Mitsubishi Tanabe's Japan diabetes alliance reflects competitive market
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) is tapping into the sales power of Daiichi Sankyo in Japan, tying up with its larger peer for the co-marketing of two pipeline oral therapies for type 2 diabetes.
You may also be interested in...
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.